VOC Sensor Array for Early Neurological Disease Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing neurological diseases such as Alzheimer's, Multiple Sclerosis, and Parkinson's face challenges due to the blood-brain barrier, making early detection difficult, and existing technologies lack sensitivity and specificity in identifying disease signatures.
Innovation Solution
A non-invasive system analyzing volatile organic compounds (VOCs) in the otic canal, either in gaseous form or as earwax, using sensors like single-walled carbon nanotubes and nano-field-effect transistors to identify disease-specific metabolic signatures with high sensitivity and reliability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional diagnostic methods are used to detect neurological diseases, then the diagnostic process can be performed with standard equipment, but the detection sensitivity and specificity are insufficient due to the blood-brain barrier
Solution Approach 1:
The patent uses volatile organic compounds (VOCs) as intermediary substances that can traverse the blood-brain barrier and carry metabolic information from the brain to external sampling locations. These VOCs serve as mediators between the protected brain environment and the external diagnostic system, enabling indirect detection of neurological disease markers without directly penetrating the blood-brain barrier.
Solution Approach 2:
The patent replaces traditional mechanical/invasive diagnostic methods (such as lumbar puncture or brain biopsy) with a chemical sensing approach. Instead of physically accessing brain tissue or cerebrospinal fluid, the system uses chemical sensors to detect VOC patterns in accessible body fluids or breath, substituting mechanical intrusion with chemical analysis.
2Reliability
If invasive methods are used to obtain brain samples for diagnosis, then direct brain tissue analysis is possible, but the procedure becomes harmful and complex
Solution Approach 1:
The patent employs VOCs as intermediary carriers that convey brain metabolic information to external sampling sites. By analyzing these intermediary substances in accessible locations (breath, saliva, or peripheral blood), the system achieves reliable diagnostic information without requiring direct brain tissue sampling, thus eliminating the harms associated with invasive procedures.
Solution Approach 2:
The patent creates a chemical copy or signature of brain metabolism through VOC profiles. Instead of analyzing actual brain tissue, the system detects a replicated metabolic signature expressed as volatile compound patterns in accessible body fluids, providing diagnostic reliability through this indirect chemical representation.
3Measurement precision
If VOC analysis is performed using conventional sensors, then the system can be built with standard technology, but the sensitivity and reliability are insufficient to detect early stage diseases
Solution Approach 1:
The patent divides the diagnostic task into multiple parallel sensing operations using an array of different sensor types. Each sensor in the array targets specific VOC categories or chemical properties, and the collective responses are integrated to create a comprehensive disease signature profile. This segmentation of the detection function across multiple specialized sensors enables high sensitivity while managing complexity through modular architecture.
Solution Approach 2:
The patent employs a composite sensing system that integrates multiple sensor technologies (such as metal oxide semiconductors, polymer sensors, and nanomaterial-based detectors) into a unified array. This composite approach leverages the complementary strengths of different sensor materials to detect diverse VOC profiles with high sensitivity and specificity, overcoming the limitations of any single sensor type.
4Loss of time
If early stage disease detection is pursued, then treatment intervention becomes more effective, but the disease signatures are more subtle and difficult to detect
Solution Approach 1:
The patent performs preliminary detection of subtle VOC pattern changes before clinical symptoms manifest. By continuously monitoring volatile compound profiles and comparing them against established baseline patterns, the system identifies early metabolic deviations that precede overt disease symptoms, enabling early intervention while the disease signatures are still detectable but not yet fully developed.
Solution Approach 2:
The patent implements a feedback-based diagnostic system that compares real-time VOC measurements against reference patterns and adjusts detection sensitivity accordingly. The system uses feedback from pattern recognition algorithms to enhance detection of subtle early-stage signatures by continuously refining the comparison between observed VOC profiles and known disease signatures, improving precision through iterative pattern matching.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection and differentiation of neurological diseases with high sensitivity and specificity by capturing disease-specific VOC patterns, overcoming the limitations of traditional diagnostic methods.
Implementation Method 1
VOC compounds which represent a particular signature or profile of a disease are comprised of small molecules that freely cross the blood brain barrier and thus are accessible and available for analysis. These compounds are products of the metabolic activities (healthy and diseased) within the brain
Implementation Method 2
using sensors like single-walled carbon nanotubes and nano-field-effect transistors to identify disease-specific metabolic signatures with high sensitivity and reliability
Data Source
AI summary
The present invention describes a non-invasive system and method for detecting early stage Alzheimer's and other autoimmune diseases associated with neurological deficits, including Multiple Sclerosis and Parkinson's Disease. By analyzing the volatile organic compounds (VOCs) found in the otic canal either in gaseous form or as what is commonly known as “earwax”, the current invention discloses how these disease signatures/profiles are illustrative of the presence or absence of a particular disease.